There have been rumors that Pfizer may acquire its own British rival GlaxoSmithKline. Deutsche Bank analyst Gregg Gilbert agreed in favor of this statement on Wednesday, saying the acquisition is valuable. In an article entitled "Introduction to Pfizer-GlaxoSmithKline" to investors, Mr. Gilbert described the full acquisition of GlaxoSmithKline as Pfizer's "material growth." Through this acquisition, Pfizer's current assets, which are now under pressure, will increase and the tax situation will improve. The Bloomberg report states, "We believe that Pfizer is eager to create wealth by balancing liquid assets. In the past, the media has pointed out the possibility of merger of the two companies, and we are now back to this topic." The report also pointed out that two After the merger of the companies, management fees can be reduced by 10% ($3.7 billion). According to a preliminary analysis by Mr. Gilbert and his colleagues, if Pfizer purchases shares of GlaxoSmithKline in the form of 1,924 pence per share and half of the cash and half of the shares, the company will bring a 10% return to Pfizer in the first year after the merger. The fourth year will bring Pfizer a 16% return. The total price of Pfizer's purchase of GlaxoSmithKline is expected to be around $146 billion (€95 billion). But both Pfizer and GlaxoSmithKline spokespersons denied the merger of the two companies. Pfizer CEO Ian Read said that at the company's strategic acquisition meeting in January, it was determined that Pfizer would acquire a company that could create value in the short term. Obviously, this is to ensure sales growth and reduce short-term costs, rather than promoting long-term new drug development. Pfizer's difficulties In the fourth quarter of 2011, Pfizer's highest-rising lipid-lowering drug Lipitor patent expired, and the company's revenue has been declining. The company's sales fell by 7% that year, falling by $16.44 billion in just one quarter. In the next few years, sales fell even more seriously. Especially in 2014, several patents for the company expired. For example, in May 2014, the anti-inflammatory drug Celebrex expired. In November, the antibacterial Zyvox expired and the erectile dysfunction drug Viagra expired. In the first quarter of 2015, sales of the main drug, Celebrex, fell by 67.15%. The drug brought 5.5% annual revenue to Pfizer in 2014. Affected by this, Pfizer's sales in the first quarter fell by 3.8% ($10.9 billion). In addition, the company holds billions of denominations of shares overseas and cannot use it in the United States without paying huge taxes. In order to get out of trouble, Pfizer made a shock to the industry last year – taking the initiative to buy the British company AstraZeneca plc. Although the company with a market value of $87 million repeatedly refused, Pfizer eventually bought shares directly from shareholders at a price of 55 pounds per share (a total of $117 billion) to take over the entire company. Pfizer-Grace Sussex merger is no easy task Although Pfizer did not successfully acquire AstraZeneca last year, according to its style, it is suspected that Pfizer will also act in the acquisition of large companies. With a total of 50,000 employees, AstraZeneca is one of the ten largest companies in the London Stock Exchange. GlaxoSmithKline is a larger company with a market capitalization of $110 billion. It has 115,000 employees worldwide and 13,000 employees in the UK alone. (AstraZeneca has only 7,000 employees in the UK). We are a supplier of high-speed rapier looms and flexible rapier looms. The company specializes in selling second-hand rapier looms and economical rapier looms. Chinese second-hand rapier looms look for Tianchi. Second-Hand Rapier Loom,High-Speed Rapier Loom,Flexible Rapier Loom,Rapier Loom Changzhou Satidi Import and Export Co., Ltd. , https://www.czguanjiechuck.com